Effect of cetuximab plus FOLFOX4 regimen on clinical outcomes in advanced gastric carcinoma patients receiving evidence-based care

Table 1 Baseline information

Classification	Research group (n = 60)	Control group (n = 57)	χ2/t	P value
Age (yr)	58.53 ± 7.49	56.84 ± 5.55	1.381	0.170
Sex (male/female)	40/20	34/23	0.619	0.431
Disease course (yr)	2.43 ± 1.01	2.23 ± 0.82	1.172	0.244
Pathological stage (IIIa/IIIb)	35/25	40/17	1.781	0.182
Differentiation degree (low/moderate or high)	21/39	22/35	0.163	0.687
Tumor diameter (cm)	3.71 ± 0.69	3.47 ± 0.79	1.753	0.082

Table 2 Effect of cetuximab + FOLFOX4 regimen on the clinical response of advanced gastric carcinoma patients receiving evidence-based care, n (%)

Classification	Research group (n = 60)	Control group (n = 57)	χ2	P value
CR	12 (20.00)	2 (3.51)
PR	39 (65.00)	27 (47.37)
SD	5 (8.33)	17 (29.82)
PD	4 (6.67)	11 (19.30)
RR	51 (85.00)	29 (50.88)	15.740	< 0.001
DCR	56 (93.33)	46 (80.70)	4.173	0.041

FOLFOX4 consists of oxaliplatin, folinic acid, and fluorouracil. CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; RR: Response rate; DCR: Disease control rate.

Table 3 Effect of cetuximab + FOLFOX4 regimen on safety in advanced gastric carcinoma patients receiving evidence-based care, n (%)

Classification	Research group (n = 60)	Control group (n = 57)	χ2	P value
Liver and kidney dysfunction	0 (0.00)	0 (0.00)
Leukopenia	1 (1.67)	1 (1.75)
Thrombocytopenia	1 (1.67)	2 (3.51)
Rash	3 (5.00)	3 (5.26)
Diarrhea	1 (1.67)	2 (3.51)
Total	6 (10.00)	8 (14.04)	0.452	0.502

FOLFOX4 consists of oxaliplatin, folinic acid, and fluorouracil.

Table 4 Influence of the cetuximab + FOLFOX4 regimen on the improvement in quality of life in advanced gastric carcinoma patients receiving evidence-based care, n (%)

Classification	Research group (n = 60)	Control group (n = 57)	χ2	P value
Enhancement	43 (71.67)	30 (52.63)	4.514	0.034
Stability	15 (25.00)	23 (40.35)	3.141	0.076
Decline	2 (3.33)	4 (7.02)	0.816	0.367

FOLFOX4 consists of oxaliplatin, folinic acid, and fluorouracil.